TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in Body weight after 24 training sessions (Kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in levels of Total cholesterol after 24 training sessions (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Night Wakenings Due to Asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Failure of device to achieve hemostasis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Sitting Systolic Blood Pressure (msSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: concentration of antibody to hepatitis A virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Bleeding Episodes Requiring Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood pressure from baseline to during and after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lung function from baseline to during and after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in fractional exhaled nitric oxide (FeNO) from baseline to during and after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cognitive symptoms of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Pathologic Complete Response (tpCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic Control (HbA1c) for Telehealth visits for COVID-19 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biopsy-verified advanced fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver-related outcomes
Primary endpoint: Mean Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of sessions until recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Returned Used Applicators Per Month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to First Perceptible Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Perceptible Pain Relief Confirmed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal intensities of lesions compared to thoracic spinal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) After 7 Days of Dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Markedly Abnormal Vital Sign Measurements
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Caregiver's Perceived Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiver's Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Biomarker level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access and Visualization in Oropharynx, Hypopharynx and Larynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in surgical strategy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of disease worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Total Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline Low density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline High density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breast cancer detection and characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Dose Limiting Toxicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Progression Free Survival at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Incidence of grade 3+ Bowel Perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Incidence of Grade 3+ Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Incidence of grade 4+ Nonhematologic Acute Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in ADCS-ADL-SIV Score at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in SIB Score at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in clotting factors level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in gas exchange over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to increase in oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relapses per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean weekly gain in weight of VLBWIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Score of Symptoms and Allergy Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All stroke
Endpoint domain: Mortality/survival
Primary endpoint: Unplanned cardiovascular hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of the main PFD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of skin remodeling parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Booster Response in Serum Bactericidal Assay Titer Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease or Suspension of Basal Insulin Delivery in Response to Hypoglycemia Challenges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increase of Basal Insulin Delivery in Response to the Hyperglycemia Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Resumption of Auto Mode Following Restored Continuous Glucose Monitoring (CGM) Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-72h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success (AHI Reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stem Cell Mobilization Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childbirth Expectancy and Experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax of Selumetinib After Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-12) of Selumetinib After Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of N-desmethyl Selumetinib After Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory response during septic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: high quality embryo rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Concentration-Time Curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Concentration-Time Curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteremia rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physical Activity Awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distal arterial flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pediatric Quality of Life Measure (Peds QL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adequacy of bowel prep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Jebsen Taylor test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Periodontal Pockets Probing Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility ratio of patients approached to recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients who complete both endoscopies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes of immunological biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with stress induced hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes of plasma thyroid hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lopinovir/Ritonavir Area Under the Concentration-time Curve (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of Lopinavir/Ritonavir (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Concentration of Lopinavir/Ritonavir (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forceplate dynamic posturography test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Time on Mechanical Ventilation or Inotrope Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change in Eczema Area Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HLA-DR expression on the surface of monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scores for Contrast Enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores for Border Delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores for Internal Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Urinary PGE-M Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Urinary LTE4 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in FDG-avidity between progressive and non-progressive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compare FDG-avidity between patients with progressive and non-progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation difficulty scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of Dilapan-S/Dilasoft insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction - delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of vaginal deliveries within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hospitalized infection or death
Endpoint domain: Mortality/survival
Primary endpoint: Patency by Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D-KEFs Tower Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail Making Test B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sustained Attention to Response Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: FAS Verbal Fluency Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of acute complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Needing an Intraoperative Autologue Blood Product Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinic Attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in sitting Diastolic Blood Pressure (siDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal voluntary force production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central and skin temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Volume Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: perceived mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in S-Anxiety subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Platelet Aggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Demyelinating brainstem plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: retinal capillary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in TNF-alpha and its receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in muscle isoforms of IGF-1 and its receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS for pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Events after AMI
Endpoint domain: Mortality/survival
Primary endpoint: ACR50 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR70 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summary of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Clinical Global Impression of Severity (CGI-S) Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Total Serum Iron, Baseline Corrected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Transferrin-bound Iron, Baseline Corrected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Total Iron Binding Capacity, Absolute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance at FLS test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Alive and Free From Respiratory Failure
Endpoint domain: Mortality/survival
Primary endpoint: Clearance of Mirikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of anterior pituitary dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in clinical measures of sensorimotor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Laryngeal View Obtained on Comarck Lehane Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Intubation Attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of Laryngeal View Obtained With 2nd Laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Kidney function post-transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decrease in SomaLogic CVD Secondary Risk Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post surgical change in degree of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post surgical change in back pain: Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from AFib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet reactivity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of patient reported psychosocial functioning score
Endpoint domain: Life impact
Endpoint subdomain: Psychosocial functioning
Primary endpoint: Change of patient reported physical functioning score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of breast cosmesis measures (excellent/good/poor)
Endpoint domain: Life impact
Endpoint subdomain: Body image
Primary endpoint: Frequency of exacerbation of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CRP Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Outcome Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived appetite and satiety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Root coverage measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean sleep-time systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with AUC for busulfan calculated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Size of change in skin flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the Beck Depression Inventory II (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: normoxia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appropriate immunization behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peer violence behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Violence Consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Postsurgical Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Relevant Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Corneal Filaments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response according to RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inflammatory versus anti-inflammatory serum cytokine fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Allergen specific IgE fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Type 2 T helper cell to Type 1 T helper cell ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With Clinical Adverse Experiences (CAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Laboratory Adverse Experiences (LAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of unbound ticagrelor and its metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of repeat EMS calls
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention